Mirum Pharmaceuticals Announces Inducement Grants for New Employees Under 2020 Plan
Reuters
Sep 11
Mirum Pharmaceuticals Announces Inducement Grants for New Employees Under 2020 Plan
Mirum Pharmaceuticals Inc. has announced the granting of inducement awards to four new employees as part of its 2020 Inducement Plan. On September 10, 2025, the Compensation Committee of the company's Board of Directors approved non-qualified stock options for the purchase of 10,820 shares of common stock and 5,390 restricted stock units (RSUs). The stock options are set at an exercise price of $74.89 per share, aligned with the closing trading price on the grant date. These options will vest over a four-year period, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months. The RSUs will vest over three years, with 33% of the shares vesting annually. These awards are contingent upon the new employees maintaining their service relationship with Mirum Pharmaceuticals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250910173678) on September 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.